Neurology · Detroit area, MI
Neurology studies in Detroit area, MI
72 recruiting studies have a site in the Detroit area. This page includes nearby cities such as Ann Arbor, Southfield, Troy, Royal Oak.
72 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Bristol-Myers Squibb
- Location
- Farmington Hills, MI + 22 other US sites
- Eligibility basics
- Ages 60–85
- RecruitingPhase 2
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
AllRock Bio, Inc.
- Location
- Ann Arbor, MI + 10 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
Eli Lilly and Company
- Location
- Farmington Hills, MI + 29 other US sites
- Eligibility basics
- Ages 55–85
- RecruitingPhase 3
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
Regeneron Pharmaceuticals
- Location
- Bloomfield Hills, MI + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
AbbVie
- Location
- Ann Arbor, MI + 25 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Hoffmann-La Roche
- Location
- Farmington Hills, MI + 52 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 2
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
Appello Pharmaceuticals, Inc.
- Location
- Ann Arbor, MI + 29 other US sites
- Eligibility basics
- Ages 30–80
- RecruitingPhase 2
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Neuron23 Inc.
- Location
- Farmington Hills, MI + 43 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 1
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
Jazz Pharmaceuticals
- Location
- Detroit, MI + 20 other US sites
- Eligibility basics
- Ages 12–75
- RecruitingPhase 2
Study of EVO756 in Adults With Migraine
Evommune, Inc.
- Location
- Ann Arbor, MI + 32 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Celgene
- Location
- Southfield, MI + 13 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 2
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures
Supernus Pharmaceuticals, Inc.
- Location
- Detroit, MI + 36 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 2
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Immunovant Sciences GmbH
- Location
- Detroit, MI + 30 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pfizer
- Location
- Ann Arbor, MI + 69 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Pfizer
- Location
- Ann Arbor, MI + 54 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
Novartis Pharmaceuticals
- Location
- Detroit, MI + 39 other US sites
- Eligibility basics
- Ages 21–70
- RecruitingPhase 2
Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease
Hillhurst Biopharmaceuticals, Inc.
- Location
- Farmington Hills, MI + 4 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 2/Phase 3
A Study of Buntanetap in Participants With PD
Annovis Bio Inc.
- Location
- Farmington Hills, MI + 26 other US sites
- Eligibility basics
- Ages 40–85
- RecruitingPhase 2
A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy
Vima Therapeutics
- Location
- Farmington Hills, MI
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
Dompé Farmaceutici S.p.A
- Location
- Ann Arbor, MI + 13 other US sites
- Eligibility basics
- Ages 50–80
- RecruitingPhase 1
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
TG Therapeutics, Inc.
- Location
- Ann Arbor, MI + 7 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations
H. Lundbeck A/S
- Location
- Farmington Hills, MI + 1 other US site
- Eligibility basics
- Ages 40–85
- RecruitingPhase 1/Phase 2
ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
Ionis Pharmaceuticals, Inc.
- Location
- Ann Arbor, MI + 4 other US sites
- Eligibility basics
- Ages 2–12
- RecruitingPhase 2
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
Zydus Therapeutics Inc.
- Location
- Detroit, MI + 13 other US sites
- Eligibility basics
- Ages 18+
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.